Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, commonly known as Vertex, is a leading biotechnology company headquartered in the United States. Founded in 1989, Vertex has established itself as a pioneer in the development of transformative therapies for serious diseases, particularly in the field of cystic fibrosis. With major operational regions across North America and Europe, the company focuses on innovative drug discovery and development. Vertex is renowned for its unique portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, and Trikafta, which have significantly improved the quality of life for patients. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as the first approved therapy for the underlying cause of cystic fibrosis. Vertex continues to drive advancements in biotechnology, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Vertex Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vertex Pharmaceuticals's score of 50 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vertex Pharmaceuticals's reported carbon emissions
In 2023, Vertex Pharmaceuticals reported total carbon emissions of approximately 488,800 kg CO2e from Scope 2 and 831,100 kg CO2e from Scope 1, alongside a significant Scope 3 emission total of about 474,129,000 kg CO2e. This brought their total Scope 1 and 2 emissions to around 13,198,000 kg CO2e. In 2022, the company recorded Scope 1 emissions of about 9,334,000 kg CO2e, Scope 2 emissions of approximately 4,285,000 kg CO2e, and Scope 3 emissions reaching about 249,816,000 kg CO2e, resulting in a total of around 13,620,000 kg CO2e for Scope 1 and 2. Vertex Pharmaceuticals has not disclosed specific reduction targets or initiatives as part of their climate commitments. However, they continue to monitor and report their emissions across all three scopes, indicating a commitment to transparency in their environmental impact. The company operates within the pharmaceutical industry, which is increasingly focusing on sustainability and reducing carbon footprints.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vertex Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
